Skip to main content

Table 4 Univariate analysis and Cox regression analysis of PFS and OS of all patients

From: Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study

Characteristics

PFS

mPFS (95%CI)

p value

Cox regression

OS

mOS (95%CI)

p value

Cox regression

HR(95%CI)

p value

HR(95%CI)

p value

Sex

 

0.187

      

 Male

7.8 (7.201–8.399)

       

 Female

13.9 (2.384–25.416)

       

Age

 

0.455

   

0.066

  

 ≤ 65

8.0 (7.465–8.535)

   

27.1 (24.519–29.681)

   

 > 65

7.7 (5.440–9.960)

   

16.5 (12.471–20.529)

   

Liver metastases

 

0.000

1.862 (1.173–2.957)

0.008

 

0.000

1.547 (0.891–2.684)

0.121

 No

8.3 (7.728–8.872)

   

27.1 (22.398–31.802)

   

 Yes

4.7 (3.997–5.403)

   

10.9 (8.966–12.834)

   

Brain metastases

 

0.903

   

0.495

  

 No

7.8 (7.182–8.418)

   

23.2 (15.251–31.149)

   

 Yes

8.0 (7.388–8.612)

   

28.2 (17.998–38.402)

   

Bone metastases

 

0.013

0.895 (0.570–1.404)

0.628

 

0.000

1.563 (0.939–2.603)

0.086

 No

8.4 (7.293–9.507)

   

29.1 (24.633–33.567)

   

 Yes

5.3 (3.887–6.713)

   

11.1 (8.102–14.098)

   

Smoking history

 

0.156

   

0.319

  

 No

8.4 (6.413–10.387)

   

26.9 (18.831–34.969)

   

 Yes

7.8 (6.938–8.662)

   

23.2 (13.258–33.142)

   

ECOG PS

 

0.015

1.670 (0.943–2.958)

0.079

 

0.028

1.563 (0.813–3.004)

0.180

 ≤ 1

8.2 (7.670–8.730)

   

26.9 (21.758–32.042)

   

 > 1

5.8 (4.150–7.450)

   

10.8 (0.000-24.847)

   

Chemotherapy regimen

 

0.505

   

0.861

  

 EP

8.2 (7.301–9.099)

   

22.8 (12.910–32.690)

   

 EC

7.8 (7.024–8.576)

   

25.6 (14.358–36.842)

   

 EL

8.2 (6.049–10.351)

   

27 (18.310–35.690)

   

Locoregional thoracic radiotherapy

 

0.000

0.422 (0.28–0.635)

0.000

 

0.000

0.540 (0.333–0.878)

0.013

 No

6.0 (4.857–7.143)

   

14.6 (10.51–18.690)

   

 Yes

12.3 (9.364–15.236)

   

32.1 (25.602–38.598)

   

LDH

 

0.021

1.163 (0.790–1.711)

0.444

 

0.002

1.580 (1.006–2.482)

0.047

 ≤ 250

8.3 (7.505–9.095)

   

27.0 (23.664–30.336)

   

 >250

7.4 (6.161–8.639)

   

14.8 (12.409–17.191)

   
  1. mOFS: median progression free survival, mOS: median overall survival